Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.72 |
| ▸ | HTR7 | P34969 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196782 | 0.98 | SIGMAR1 (0.73) | SIGMAR1HTR7KDM4ELMNASMN1; SMN2 | |
| SCHEMBL5198457 | 0.90 | HTR7 (0.74) | SIGMAR1HTR7KDM4ELMNASMN1; SMN2 | |
| SCHEMBL17374138 | 0.87 | HTR7 (0.66) | SIGMAR1HTR7KDM4ELMNASMN1; SMN2 | |
| SCHEMBL4617661 | 0.87 | SFRP1 (0.61) | SIGMAR1HTR7KDM4ELMNASMN1; SMN2 | |
| SCHEMBL3719058 | 0.86 | PKM (0.69) | HTR7ALDH1A1PKM | |
| SCHEMBL3889428 | 0.86 | HTR7 (0.68) | SIGMAR1HTR7KDM4ELMNASMN1; SMN2 | |
| SCHEMBL29172771 | 0.86 | HTR7 (0.60) | SIGMAR1HTR7KDM4ELMNASMN1; SMN2 | |
| SCHEMBL13297961 | 0.84 | L3MBTL1 (0.83) | SIGMAR1KDM4ELMNASMN1; SMN2GAA | |
| SCHEMBL6291993 | 0.84 | SIGMAR1 (0.68) | SIGMAR1HTR7KDM4ELMNASMN1; SMN2 | |
| SCHEMBL3330416 | 0.84 | SIGMAR1 (0.73) | SIGMAR1KDM4ELMNASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101426772-B | Benzotriazine inhibitors of kinases | TARGEGEN INC | 2014-01-08 | — | — | CN | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| EP-1443041-A1 | 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | SIGMAR1 1178/4885HTR7 1626/4885KDM4E 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.